Imperial Oil Limited Common Stock vs TransMedics Group Inc — how do they compare? Imperial Oil Limited Common Stock trades at $129.79 (market cap $62.87B), while TransMedics Group Inc trades at $75.02 (market cap $2.62B). The key difference: Imperial Oil Limited Common Stock is far larger — about 24× TransMedics Group Inc's market cap, and Imperial Oil Limited Common Stock pays a 1.89% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| IMO | TMDX | |
|---|---|---|
Market Cap | $62.87B | $2.62B |
Volume | 507,550 | 891,435 |
Sector | Energy | Health |
52-Week High | $138.33 | $150.42 |
52-Week Low | $83.72 | $61.99 |
Enterprise Value | $63.78B | $3.01B |
Dividend Yield | 1.89% | — |
Typical Hold Time | — | 24 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics Group (TMDX) trades at $79.135, up 1.23% on the day, but faces a bearish technical signal with recent earnings misses in Q1 and Q2 2026. The company maintains strong profitability with a 58.69% gross margin and 22.69% net margin, though net income is projected to decline in 2026. Recent news highlights insider buying and CFO appointment, but also ongoing legal investigations into fiduciary duties.
The stock presents a mixed outlook; analyst consensus is bullish with a $99.63 price target, but risks include margin pressure from heavy investment and legal overhangs. Upside hinges on execution against guidance, while downside is cushioned by solid cash flow and institutional support.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →